{"filing":{"accession_number":"0001213900-26-062935","cik":"0001388320","ticker":"ATNM","company_name":"Actinium Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-05-29","report_date":null,"primary_document":"ea0292691-8k_actinium.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1388320/000121390026062935/ea0292691-8k_actinium.htm"},"events":[{"id":8165,"run_id":7167,"accession_number":"0001213900-26-062935","anchor_item_number":"3.01","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.98,"summary":"Actinium Pharmaceuticals received a notice from NYSE American on May 27, 2026, indicating non-compliance with continued listing standards due to stockholders' equity of $2.3 million falling below the required $4.0 million threshold while reporting net losses in five consecutive fiscal years. The company must submit a compliance plan by June 26, 2026, or face delisting proceedings.","company_name":"Actinium Pharmaceuticals, Inc.","ticker":"ATNM","filing_date":"2026-05-29","submitted_at":null,"items":[{"id":2774,"accession_number":"0001213900-26-062935","item_number":"3.01","item_title":"Notice of Delisting or Failure to Satisfy a Continued","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.98,"reasoning":"Actinium Pharmaceuticals received a notice from NYSE American on May 27, 2026, indicating non-compliance with continued listing standards under Section 1003(a)(ii) of the NYSE American Company Guide due to stockholders' equity of $2.3 million falling below the required $4.0 million threshold while reporting net losses in five consecutive fiscal years. The company must submit a compliance plan by June 26, 2026, or face delisting proceedings, with a Plan Period Deadline of November 27, 2027. This is a classic delisting risk disclosure that would materially affect investor assessment of the registrant's ability to maintain its public listing.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-30T02:33:27.708270+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":8166,"run_id":7167,"accession_number":"0001213900-26-062935","anchor_item_number":"7.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"summary":"The company provided a material update on the development program for ATNM-400, a product candidate, disclosed via press release in connection with receipt of a Notice.","company_name":"Actinium Pharmaceuticals, Inc.","ticker":"ATNM","filing_date":"2026-05-29","submitted_at":null,"items":[{"id":2775,"accession_number":"0001213900-26-062935","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"reasoning":"The filing discloses receipt of a \"Notice\" and provides an update on the development program for ATNM-400, a product candidate. While the specific nature of the Notice is not detailed in the excerpt provided, the fact that the company issued a press release to announce it and provide a material update on a key product candidate suggests this is a material disclosure. Without clarity on whether this is a regulatory approval, clinical trial result, or other specific event type, \"other_material\" is the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-30T02:33:27.708270+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":2774,"accession_number":"0001213900-26-062935","item_number":"3.01","item_title":"Notice of Delisting or Failure to Satisfy a Continued","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.98,"reasoning":"Actinium Pharmaceuticals received a notice from NYSE American on May 27, 2026, indicating non-compliance with continued listing standards under Section 1003(a)(ii) of the NYSE American Company Guide due to stockholders' equity of $2.3 million falling below the required $4.0 million threshold while reporting net losses in five consecutive fiscal years. The company must submit a compliance plan by June 26, 2026, or face delisting proceedings, with a Plan Period Deadline of November 27, 2027. This is a classic delisting risk disclosure that would materially affect investor assessment of the registrant's ability to maintain its public listing.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-30T02:33:27.708270+00:00","company_name":"Actinium Pharmaceuticals, Inc.","ticker":"ATNM","filing_date":"2026-05-29"},{"id":2775,"accession_number":"0001213900-26-062935","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"reasoning":"The filing discloses receipt of a \"Notice\" and provides an update on the development program for ATNM-400, a product candidate. While the specific nature of the Notice is not detailed in the excerpt provided, the fact that the company issued a press release to announce it and provide a material update on a key product candidate suggests this is a material disclosure. Without clarity on whether this is a regulatory approval, clinical trial result, or other specific event type, \"other_material\" is the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-30T02:33:27.708270+00:00","company_name":"Actinium Pharmaceuticals, Inc.","ticker":"ATNM","filing_date":"2026-05-29"}]}